Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

News Daily News

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

Michael O'Riordan

December 08, 2022

TRANSFORM-HF: Torsemide No Better Than Furosemide for Hospitalized HF

News Conference News AHA 2022

TRANSFORM-HF: Torsemide No Better Than Furosemide for Hospitalized HF

November 05, 2022

GDMT With ARNI Lessens MR, Perhaps Obviating Need for Interventions

News Conference News HFSA 2022

GDMT With ARNI Linked to Less MR, May Obviate Need for Interventions

Michael O'Riordan

October 04, 2022

Sacubitril/Valsartan Versus Ramipril for Patients with Acute Myocardial Infarction: Win-ratio Analysis of the PARADISE-MI Trial

Presentation ESC 2022

Sacubitril/Valsartan Versus Ramipril for Patients with Acute Myocardial Infarction: Win-ratio Analysis of the PARADISE-MI Trial

Presenter: Otavio Berwanger

August 29, 2022

No Hints of Cognitive Defects With ARNIs in HFpEF

News Conference News ESC 2022

No Hints of Cognitive Defects With ARNIs in HFpEF: PERSPECTIVE

August 26, 2022

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

News Daily News

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

July 25, 2022

Dapagliflozin Boosts Health Status Across LVEF Range

News Conference News ESC Heart Failure 2022

Dapagliflozin Boosts Health Status Across LVEF Range

May 23, 2022

Gains in HF Drug Therapy Raise Questions About ICD Benefit in Modern Era

News Conference News HRS 2022

Gains in HF Drug Therapy Raise Questions About ICD Benefit in Modern Era

May 02, 2022

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

News Daily News

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

Michael O'Riordan

January 27, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.